Multiparametric MRI for prostate cancer detection: Performance in patients with prostate-specific antigen values between 2.5 and 10 ng/mL

Abstract

The cMRI score could identify patients with a PSA≤10 ng/mL who will have a negative work-up, for its high negative predictive value, and patients at high risk for significant prostate cancer because of its correlation with the Gleason score

Prebiopsy multiparametric MRI‐based risk score for predicting prostate cancer in biopsy‐naive men with prostate‐specific antigen between 4–10 ng/mL

“…[6][7][8][9] A multiparametric MRI (mpMRI), combining both morphological MR with physiological MR techniques (for example, diffusion-weighted [DW] MRI and MR spectroscopic imaging [MRSI]), has been shown to improve detection, localization, staging, and assessment of the aggressiveness of PCa noninvasively. [10][11][12][13][14][15][16][17][18] mpMRI-targeted biopsy has been shown to reduce sampling errors associated with standard 12-core transrectal ultrasound (TRUS)-guided biopsy. [19][20][21] However, handling of large quantitative data generated from mpMRI requires an automated datahandling process.…”

Prostate cancer detection using quantitative T2 and T2‐weighted imaging: The effects of 5‐alpha‐reductase inhibitors in men on active surveillance

“…1 Today, mpMRI plays a pivotal role in the diagnosis and risk stratification of men with prostate cancer. 1 Today, mpMRI plays a pivotal role in the diagnosis and risk stratification of men with prostate cancer.…”

“…M ultiparametric magnetic resonance imaging (mpMRI) combines high-resolution T 2 -weighted imaging (T 2 -WI) sequences with dynamic contrast-enhanced (DCE) and diffusion-weighted imaging (DWI), and/or spectroscopy. 1 Today, mpMRI plays a pivotal role in the diagnosis and risk stratification of men with prostate cancer. 2 The key sequences that drive this process are T 2 -WI and DWI, with DCE providing useful input in select cases.…”

Improving non-invasive detection of prostate cancer using diffusion-weighted MRI

“…Petrillo et al [40] focused on 136 intermediate risk patients with PSA 2.5-10. Of these, 119 had PSA scores between 4 to 10 and 17 had scores between 2.5 to 4.…”